Bolt Biotherapeutics has acquired Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multi-specific antibodies designed to deliver best-in-disease therapies
Following the acquisition, the company will focus on advancing Prana’s pipeline of half-life-extended multi-specific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a phase 2 study in eosinophilic esophagitis (EoE) planned.
